Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.33/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBIO Hot Sheet
Join SI Premium – FREE
Eleven Biotherapeutics (NASDAQ: EBIO) reported Q1 EPS of ($0.33), versus ($0.36) reported last year. Revenue for the quarter came in at $277 thousand, versus $114 thousand reported last year.
For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Vistra stock sinks ahead of earnings report
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
